Anti-CD19 and anti-CD22 monoclonal antibodies increase the effectiveness of chemotherapy in Pre-B acute lymphoblastic leukemia cell lines

Leuk Res. 2008 Apr;32(4):625-32. doi: 10.1016/j.leukres.2007.07.002. Epub 2007 Aug 15.


The monoclonal antibodies (MAbs) HD37 and RFB4 bind to receptors on precursor B acute lymphoblastic leukemia (ALL) cells. These MAbs were tested alone and in combination with chemotherapy for their anti-leukemic activity. HD37 and not RFB4 increased the in vitro cytotoxicity of daunorubicin (DNR) and vincristine (VCR) in three Pre-B ALL cell lines. HD37 alone induced apoptosis in 30% of the cells versus 2% for RFB4. The treatment of SCID/ALL mice with either chemotherapy agent minimally prolonged their mean survival time (MST) versus controls but HD37 or RFB4 plus VCR significantly extended the MST. Forty percent of the mice treated with HD37 plus VCR survived. In conclusion, chemotherapy was made more effective when combined with HD37, and less so with RFB4.

Publication types

  • Comparative Study
  • Research Support, N.I.H., Extramural

MeSH terms

  • Acute Disease
  • Animals
  • Antibiotics, Antineoplastic / therapeutic use*
  • Antibodies, Monoclonal / therapeutic use*
  • Antigens, CD19 / immunology*
  • Antineoplastic Agents, Phytogenic / therapeutic use*
  • Apoptosis / drug effects
  • Daunorubicin / therapeutic use
  • Drug Synergism
  • Humans
  • Male
  • Mice
  • Mice, SCID
  • Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / drug therapy*
  • Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / immunology
  • Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / pathology
  • Sialic Acid Binding Ig-like Lectin 2 / immunology*
  • Survival Rate
  • Tumor Cells, Cultured
  • Vincristine / therapeutic use


  • Antibiotics, Antineoplastic
  • Antibodies, Monoclonal
  • Antigens, CD19
  • Antineoplastic Agents, Phytogenic
  • Sialic Acid Binding Ig-like Lectin 2
  • Vincristine
  • Daunorubicin